Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jakub, Żołnierek"'
Autor:
Jakub Żołnierek
Publikováno v:
OncoReview. 11:80-84
Prostate cancer is one of the most frequently diagnosed cancers in men. Number of newly diagnosed cases is increasing due to several factors and the most important ones seem to be: population ageing and more sensitive diagnostic procedures. Secondary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37b481e3cba51ac3a5ebccedd541183e
https://doi.org/10.24292/01.or.123300921.1
https://doi.org/10.24292/01.or.123300921.1
Autor:
Toni K, Choueiri, Thomas, Powles, Mauricio, Burotto, Bernard, Escudier, Maria T, Bourlon, Bogdan, Zurawski, Victor M, Oyervides Juárez, James J, Hsieh, Umberto, Basso, Amishi Y, Shah, Cristina, Suárez, Alketa, Hamzaj, Jeffrey C, Goh, Carlos, Barrios, Martin, Richardet, Camillo, Porta, Rubén, Kowalyszyn, Juan P, Feregrino, Jakub, Żołnierek, David, Pook, Elizabeth R, Kessler, Yoshihiko, Tomita, Ryuichi, Mizuno, Jens, Bedke, Joshua, Zhang, Matthew A, Maurer, Burcin, Simsek, Flavia, Ejzykowicz, Gisela M, Schwab, Andrea B, Apolo, Robert J, Motzer, Suresh, Nair
Publikováno v:
New England Journal of Medicine. 384:829-841
The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known.In this phase 3, randomized, open-label trial, we randomly assigned adults
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f3eeff33916cf81fbd615dd2954664f
https://doi.org/10.1056/nejmoa2026982
https://doi.org/10.1056/nejmoa2026982
Autor:
Jakub Żołnierek
Publikováno v:
Oncology in Clinical Practice. 15:303-306
Prostate cancer is one of the most common tumours in the human population and the most frequently diagnosed among genitourinary tumours. Despite relatively high efficacy of systemic treatment in prostate cancer, it is still one of the most important
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f35f31bd720576e6ab6ee2faa1cb16f
https://doi.org/10.5603/ocp.2019.0026
https://doi.org/10.5603/ocp.2019.0026
Autor:
Wojciech Poborski, Piotr J. Wysocki, Jakub Kucharz, Karolina Skalska, Małgorzata Gola, Wojciech Rogowski, Bogumiła Arłukowicz-Czartoryska, Jakub Żołnierek
Publikováno v:
Oncology in Clinical Practice. 15:281-288
Introduction. Cabazitaxel has been approved by the FDA and EMEA for the treatment of metastatic castration- resistant prostate cancer (mCRPC) after failure of docetaxel-based chemotherapy. Between June 2011 and November 2013 cabazitaxel was reimburse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4028521fcd2e7cf6cf97e020b5a072e4
https://doi.org/10.5603/ocp.2019.0033
https://doi.org/10.5603/ocp.2019.0033
Autor:
Wojciech Rogowski, Jakub Żołnierek, Aneta Lebiedzińska, Ewa Wachuła, Beata Kos-Kudła, Violeta Sulżyc-Bielicka, Ewa Iżycka-Świeszewska, Anita Gorzelak
Publikováno v:
Endokrynologia Polska. 70:313-317
Introduction: Many retrospective studies have confirmed that capecitabine combined with temozolomide is effective in neuroendocrine neoplasms. Most of the studies focused on grade 1 and grade 2 neuroendocrine tumours, mainly of pancreatic origin. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f3239016f227910beac6d9338a70b87
https://doi.org/10.5603/ep.a2019.0010
https://doi.org/10.5603/ep.a2019.0010
Autor:
Wojciech Poborski, Piotr Tomczak, Lubomir Bodnar, Jakub Żołnierek, Rafał Stec, Anna M. Czarnecka, Cezary Szczylik, Przemysław Langiewicz
Publikováno v:
Nowotwory. Journal of Oncology. 64:443-453
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7369f7303937c8a45ca93a980ad1ea8
https://doi.org/10.5603/njo.2014.0072
https://doi.org/10.5603/njo.2014.0072
Autor:
Jakub Żołnierek
Publikováno v:
Współczesna Onkologia. 5:293-304
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4116cd67de5a10a2e6ce655bc18f8b75
https://doi.org/10.5114/wo.2011.25658
https://doi.org/10.5114/wo.2011.25658
Autor:
Tomasz Syryło, Jakub Żołnierek, Leszek Bortnowski, Henryk Zieliński, Cezary Szczylik, Andrzej Bogdanowicz
Publikováno v:
Współczesna Onkologia. 1:39-43
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff593b410dfca341261a49999f9a1001
https://doi.org/10.5114/wo.2010.977
https://doi.org/10.5114/wo.2010.977
Autor:
Jakub Żołnierek
Publikováno v:
Historia@Teoria. 2:223
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0449ce0afb4ba5344c0ddadf276ab3c0
https://doi.org/10.14746/ht.2017.3.1.22
https://doi.org/10.14746/ht.2017.3.1.22
Autor:
Anna Waśko-Grabowska, Grzegorz Opolski, Sebastian Szmit, Jakub Żołnierek, Paweł Nurzyński, Magdalena Zaborowska, Krzysztof J. Filipiak, Cezary Szczylik
Publikováno v:
Kidneyblood pressure research. 35(6)
Background/Aims: The purpose of the present study was to determine the relationship between iatrogenic arterial hypertension or baseline cardiovascular comorbidities and outcomes in metastatic renal cell cancer (mRCC) patients treated with sorafenib.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f10c80ee750d5c38b4c7bba14f4b5412
https://pubmed.ncbi.nlm.nih.gov/22688785
https://pubmed.ncbi.nlm.nih.gov/22688785